adalimumab vs certolizumab pegol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00055497 · Phase 3 · completed
Design meets top-tier criteria (randomized, quadruple-blind, placebo-controlled, hard clinical endpoint), but the randomized comparison population was very small (only 55 total randomized participants across 3 arms) and the two primary analysis methods gave discordant significance results (NRI missed, LOCF met), which per the definitions caps this at moderate under both the underpowered-n and mixed/unclear-primary-result tests.
Next expected readout: June 2027 · NCT06045754 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) (met)
Result source: NCT02499783
certolizumab pegol · Cimzia
Marketed by UCB
NCT00552344 · Phase 3 · completed
This open-label study gave long-term certolizumab pegol to patients with Crohn's disease from study C87085. Its primary objective was safety and its primary outcomes were adverse events, so there is no efficacy result to call met or missed. Over up to 272 weeks, 89.6% of patients had an adverse event and 37.1% a serious one. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Percentage of Subjects in Clinical Remission at Week 6: Clinical remission at Week 6: 31.6% (95% CI 25.4-37.8) certolizumab pegol vs 25.4% (95% CI 19.5-31.3) placebo; no p-value reported (missed)
Result source: NCT00552058
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | certolizumab pegol |
|---|---|---|
| Clinical remission (induction) | 37.3% vs 6.8%+30.5 vs placeboNCT024997831 other result
| 31.6% vs 25.4%+6.2 vs placeboNCT005520582 other results
|
| Endoscopic response (induction) | —Trial running · NCT05040464 | —Not posted · NCT00152425 |
| Clinical remission (maintenance) | 47.4% vs 33.3%+14.1 vs placeboNCT0005549711 other results
| 37.5% vs 35%+2.5 vs placeboNCT003564081 other result
|
| Endoscopic response (maintenance) | —Trial running · NCT05040464 | —Not posted · NCT00152425 |
Clinical remission (induction)
- adalimumab
- 37.3% vs 6.8%+30.5 vs placeboNCT02499783
1 other result
- 46.9% vs 27.7% NCT00348283
- certolizumab pegol
- 31.6% vs 25.4%+6.2 vs placeboNCT00552058
2 other results
- 26.5% vs 19.1% NCT00552058
- 23.3% vs 15.8% NCT00552058
Endoscopic response (induction)
- adalimumab
- —Trial running · NCT05040464
- certolizumab pegol
- —Not posted · NCT00152425
Clinical remission (maintenance)
- adalimumab
- 47.4% vs 33.3%+14.1 vs placeboNCT00055497
11 other results
- 66.7% vs 33.3% NCT00055497
- 78.9% vs 44.4% NCT00055497
- 83.3% vs 44.4% NCT00055497
- 38.1% vs 9.1% NCT00445432
- 36.3% vs 38.9% NCT00055497
- 40.2% vs 38.9% NCT00055497
- 32.8% vs 9.2% NCT00348283
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- certolizumab pegol
- 37.5% vs 35%+2.5 vs placeboNCT00356408
1 other result
- 3% vs 35% NCT00356408
Endoscopic response (maintenance)
- adalimumab
- —Trial running · NCT05040464
- certolizumab pegol
- —Not posted · NCT00152425
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. adalimumab: 11 of 11 rows · certolizumab pegol: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | certolizumab pegol Rows use multiple source trials |
|---|---|---|
| CDAI responder rate · % of participants Induction | 67.6% (n=102) vs 27.2% (n=103) placebo @ 4wk160/80 mga NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 | 35.3% (n=215) vs 26.3% (n=209) placebo @ 4wka NCT00552058 · Phase 3 · monotherapy |
| CDAI responder rate · % of participants No placebo or comparator arm | 83.4% (n=308) @ 12wkb,a,c NCT02065570 · Phase 3 · monotherapy show 1 more dose74.8% (n=206) @ 12wk NCT02065570 · Phase 3 · monotherapy | 53.3% (n=229)400 mga,c NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 1 other source trial32.6% (n=89) @ 54wk400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 |
| CDAI absolute change · score No placebo or comparator arm | -185.24 score @ 10wkLow Induction Doseb,d,a,e,c NCT02015793 · Phase 2 · registry result, not featured evidence show 1 more dose-182.87 score @ 10wkStandard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence | -121.52 score400 mgd,a,e,c NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 1 other source trial-148.82 score @ 10wk400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 |
| Clinical Remission responder rate · % of participants No placebo or comparator arm | 60% (n=55) @ 10wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)f,a,g NCT02764762 · Phase 4 · registry result, not featured evidence · combination 2 other source trials66.7% (n=15) @ 10wkLow Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 66.7% (n=15) @ 10wkStandard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence | 46.1% (n=89) @ 10wk400 mgf,a,g NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 |
| Endoscopic responder rate · % of participants No placebo or comparator arm | 56.4% (n=55) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)f,a,g,h NCT02764762 · Phase 4 · registry result, not featured evidence · combination | 62.3% (n=53) @ 54wk400 mgb,f,a,g,h NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 show 1 more dose39.3% (n=28) @ 54wk400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 |
| Endoscopic Remission responder rate · % of participants No placebo or comparator arm | 34.5% (n=55) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)f,a,g,h NCT02764762 · Phase 4 · registry result, not featured evidence · combination | 28.3% (n=53) @ 54wk400 mgb,f,a,g,h NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 show 1 more dose32.1% (n=28) @ 54wk400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 |
| IBDQ Remission responder rate · % of participants Induction | 40.2% (n=102) vs 20.4% (n=103) placebo @ 4wk160/80 mga NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 | 33.5% (n=215) vs 23.9% (n=209) placebo @ 4wka NCT00552058 · Phase 3 · monotherapy |
| Dropout rate | —40 mg every other weeki NCT00055497 · Phase 3 show 34 more results15.8%40 mg every other week NCT00055497 · Phase 3 11.1%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 40.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 48.5% NCT00195715 · Phase 3 16.9%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.4% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 6.8%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 6.8%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 21.4% NCT02185014 · Phase 3 · monotherapy 61% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 60%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 34.4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 35.7%80 mg NCT01958827 · Phase 3 · monotherapy 16.4%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 36% NCT02148718 · Phase 4 · registry result, not featured evidence 26.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 26.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence | 78.4%j NCT00552344 · Phase 3 · monotherapy show 24 more results80.3% NCT00160524 · Phase 3 · monotherapy —400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy —400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 69.5%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 92.3% NCT00160706 · Phase 3 · monotherapy —400 mg NCT00356408 · Phase 3 · monotherapy —CDP870/Completer NCT00356408 · Phase 3 · monotherapy —CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 7.2% NCT00552058 · Phase 3 · monotherapy 40.4%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence 46.2%400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence 53.3%400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 25%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence 3.1%400 mg NCT00291668 · Phase 2 · registry result, not featured evidence 3.3%200 mg NCT00291668 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —40 mg every other weeki NCT00055497 · Phase 3 show 34 more results5.3%40 mg every other week NCT00055497 · Phase 3 5.6%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 12.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 15.7% NCT00195715 · Phase 3 6%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 1.5% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 3.9%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 2.4%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 7.1% NCT02185014 · Phase 3 · monotherapy 8% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 21.9%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 10.7%80 mg NCT01958827 · Phase 3 · monotherapy 10.9%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination — NCT02148718 · Phase 4 · registry result, not featured evidence 20%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 20%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence | —j NCT00552344 · Phase 3 · monotherapy show 24 more results35.8% NCT00160524 · Phase 3 · monotherapy —400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy —400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 18.9%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 51% NCT00160706 · Phase 3 · monotherapy —400 mg NCT00356408 · Phase 3 · monotherapy —CDP870/Completer NCT00356408 · Phase 3 · monotherapy —CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 3.6% NCT00552058 · Phase 3 · monotherapy 14.6%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence —Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence —400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence —400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 12.5%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence —400 mg NCT00291668 · Phase 2 · registry result, not featured evidence —200 mg NCT00291668 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 5.3%40 mg every other weeki NCT00055497 · Phase 3 show 34 more results—40 mg every other week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 0%40 mg every week NCT00055497 · Phase 3 16.7%40 mg NCT00055497 · Phase 3 2%160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 38.1% NCT00195715 · Phase 3 —40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 14.8% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.5%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 4.9%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy 4.6%Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy 6.4%Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 10.7% NCT02185014 · Phase 3 · monotherapy 48% NCT00686374 · Phase 3 · monotherapy 23.7%40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20%20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 8%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 40.6%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 28.6%80 mg NCT01958827 · Phase 3 · monotherapy —40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 2.3% NCT02148718 · Phase 4 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 7.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 14.3%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence | 37.1%j NCT00552344 · Phase 3 · monotherapy show 24 more results40.3% NCT00160524 · Phase 3 · monotherapy 13.4%400 mg every 2 weeks NCT00308581 · Phase 3 · monotherapy 13.4%400 mg every 4 weeks NCT00308581 · Phase 3 · monotherapy 31.9%400 mg NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 44.5% NCT00160706 · Phase 3 · monotherapy 14.6%400 mg NCT00356408 · Phase 3 · monotherapy 0%CDP870/Completer NCT00356408 · Phase 3 · monotherapy 12.1%CDP870/Non-completer NCT00356408 · Phase 3 · monotherapy 5.4% NCT00552058 · Phase 3 · monotherapy 38.2%400 mg NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 0%Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 0%Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 40%High-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence 0%Low-dose (Weight Adjusted) NCT01190410 · Phase 2 · registry result, not featured evidence 50%Re-Induction NCT01190410 · Phase 2 · registry result, not featured evidence 23.1%400 mg / 200 mg NCT00329420 · Phase 2 · registry result, not featured evidence 26.7%400 mg / 400 mg NCT00329420 · Phase 2 · registry result, not featured evidence 33.3%CZP 400 mg / CZP 200 mg NCT00329550 · Phase 2 · registry result, not featured evidence 31.3%CZP 400 mg / CZP 400 mg NCT00329550 · Phase 2 · registry result, not featured evidence 9.4%400 mg NCT00291668 · Phase 2 · registry result, not featured evidence 3.3%200 mg NCT00291668 · Phase 2 · registry result, not featured evidence —400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 20%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 26.7%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 40 mg every other weeki nasopharyngitis 26.3% (placebo 38.9%) crohn's disease aggravated 21.1% (placebo 27.8%) sinusitis 21.1% (placebo 5.6%) NCT00055497 · Phase 3 show 28 more results40 mg every week crohn's disease aggravated 11.1% (placebo 27.8%) dizziness (excl vertigo) 11.1% (placebo 5.6%) nasopharyngitis 11.1% (placebo 38.9%) NCT00055497 · Phase 3 40 mg crohn's disease aggravated 17.6% (placebo 27.8%) nasopharyngitis 16.7% (placebo 38.9%) headache 14% (placebo 11.1%) NCT00055497 · Phase 3 160/80 mg white blood cell count decreased 5.9% (placebo 1%) cough 4.9% (placebo 0%) dizziness 3.9% (placebo 0%) NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg every other week or every week headache 18.9% nasopharyngitis 14.4% arthralgia 7.6% NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 crohn's disease 23.4% (placebo 29.2%) headache 14.1% (placebo 9.2%) nasopharyngitis 14.1% (placebo 12.3%) NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 viral upper respiratory tract infection 39% headache 37% upper respiratory tract infection 31% NCT00686374 · Phase 3 · monotherapy 40 mg or 20 mg every other week headache 17.2% crohn's disease 11.8% nausea 10.8% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20 mg or 10 mg every other week headache 21.1% crohn's disease 15.8% nasopharyngitis 11.6% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg Eow nasopharyngitis 56% (placebo 12%) rhinorrhoea 16% (placebo 0%) adverse drug reaction 12% (placebo 4%) NCT00445432 · Phase 2/3 · monotherapy 40 mg Eow nasopharyngitis 71.9% (placebo 12%) adverse drug reaction 18.8% (placebo 4%) iron deficiency anaemia 18.8% (placebo 0%) NCT00445432 · Phase 2/3 · monotherapy 160 mg/80 mg + 40/40 mg adverse drug reaction 11.1% (placebo 4.3%) application site swelling 11.1% (placebo 0%) blood creatine phosphokinase (at investigator's discretion) 11.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 160 mg/80 mg headache 9.1% (placebo 4.3%) upper respiratory tract infection 9.1% (placebo 4.3%) abdominal distension 6.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80/40 mg + 40/40 mg headache 16.7% (placebo 4.3%) abdominal distension 8.3% (placebo 0%) abdominal pain 8.3% (placebo 4.3%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80 mg/40 mg injection site reaction 8.8% (placebo 8.7%) malaise 8.8% (placebo 0%) rhinorrhoea 8.8% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 40 mg every other week crohn's disease 16.1% abdominal pain 7.6% injection site reaction 7.6% NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) arthralgia 18.2% crohn's disease 16.4% nasopharyngitis 10.9% NCT02764762 · Phase 4 · registry result, not featured evidence · combination vomiting 7% abdominal mass 5.8% arthralgia 4.7% NCT02148718 · Phase 4 · registry result, not featured evidence Low Induction Dose leukopenia 20% pyrexia 13.3% arthralgia 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Low Induction Dose leukopenia 15.4% animal bite 7.7% aphthous stomatitis 7.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose alanine aminotransferase increased 13.3% aspartate aminotransferase increased 13.3% abdominal pain 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose mycobacterium tuberculosis complex test positive 14.3% aspartate aminotransferase increased 7.1% asthenia 7.1% NCT02015793 · Phase 2 · registry result, not featured evidence | j crohn's disease 31.6% abdominal pain 18.7% upper respiratory tract infection 15.7% NCT00552344 · Phase 3 · monotherapy show 21 more results400 mg every 2 weeks nasopharyngitis 17.2% pyrexia 11.8% arthralgia 10.8% NCT00308581 · Phase 3 · monotherapy 400 mg every 4 weeks headache 16.6% nasopharyngitis 12.3% nausea 11.2% NCT00308581 · Phase 3 · monotherapy 400 mg nasopharyngitis 27.5% headache 20.5% pyrexia 20.5% NCT00333788 · Phase 3 · monotherapy · Crohn's Disease · phase 3 400 mg crohn's disease 21.4% (placebo 7.1%) arthralgia 18.4% (placebo 0%) upper respiratory tract infection 13.6% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy arthralgia 25% (placebo 0%) myalgia 18.8% (placebo 0%) sinusitis 18.8% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy crohn's disease 33.3% (placebo 7.1%) arthralgia 21.2% (placebo 0%) nausea 18.2% (placebo 7.1%) NCT00356408 · Phase 3 · monotherapy headache 5.4% (placebo 4.7%) abdominal pain 4.5% (placebo 3.7%) arthralgia 4% (placebo 2.8%) NCT00552058 · Phase 3 · monotherapy 400 mg headache 33.7% arthralgia 30.3% nasopharyngitis 23.6% NCT00297648 · Phase 3 · monotherapy · Crohn's Disease · phase 3 High-dose (Weight Adjusted) abdominal pain upper 40% nasopharyngitis 20% nausea 20% NCT01190410 · Phase 2 · registry result, not featured evidence Low-dose (Weight Adjusted) asthma exercise induced 25% cough 25% dizziness 25% NCT01190410 · Phase 2 · registry result, not featured evidence Re-Induction abdominal injury 50% anal fissure 50% c-reactive protein increased 50% NCT01190410 · Phase 2 · registry result, not featured evidence 400 mg / 200 mg pyrexia 46.2% (placebo 11.1%) nasopharyngitis 38.5% (placebo 55.6%) contusion 15.4% (placebo 0%) NCT00329420 · Phase 2 · registry result, not featured evidence 400 mg / 400 mg nasopharyngitis 40% (placebo 55.6%) pyrexia 20% (placebo 11.1%) nausea 13.3% (placebo 5.6%) NCT00329420 · Phase 2 · registry result, not featured evidence nasopharyngitis 20% (placebo 22.2%) nausea 13.3% (placebo 22.2%) urinary tract infection 13.3% (placebo 0%) NCT00329550 · Phase 2 · registry result, not featured evidence nasopharyngitis 62.5% (placebo 22.2%) dna antibody positive 12.5% (placebo 22.2%) headache 12.5% (placebo 0%) NCT00329550 · Phase 2 · registry result, not featured evidence 400 mg nasopharyngitis 21.9% (placebo 31.3%) nausea 6.3% (placebo 3.1%) pharynx discomfort 6.3% (placebo 0%) NCT00291668 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 23.3% (placebo 31.3%) nausea 6.7% (placebo 3.1%) pharyngolaryngeal pain 6.7% (placebo 0%) NCT00291668 · Phase 2 · registry result, not featured evidence 400 mg Q4W influenza 40% cystitis 20% foetal vascular malperfusion 20% NCT04163016 · Phase 1 · registry result, not featured evidence 200 mg Q2W covid-19 40% headache 20% hypertension 13.3% NCT04163016 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- cThe assessment timepoint is not available for both results.
- dTrial phases differ: Phase 2 versus Phase 3.
- eTreatment context has not been resolved for both arms.
- fTrial phases differ: Phase 4 versus Phase 3.
- gTreatment context differs: combination versus monotherapy.
- hAssessment timepoints differ: 26 weeks versus 54 weeks.
- iPopulation comparability has not been reviewed for 24 of these studies.
- jPopulation comparability has not been reviewed for 21 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 11 more results
show 11 more results
show 6 more results
show 4 more results
show 1 more result
+ 53 further endpoints in the CSV export.
certolizumab pegol
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 19 more results
show 19 more results
show 1 more result
show 17 more results
show 17 more results
+ 19 further endpoints in the CSV export.
Psoriatic Arthritis
Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07398651 (registry estimate)
No aligned efficacy figure on record for this race.
certolizumab pegol · Cimzia
Marketed by UCB
NCT03357471 · Phase 3 · completed
Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.
No aligned efficacy figure on record for this race.
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | certolizumab pegol |
|---|---|---|
| ACR20 | —Not posted · NCT00646178 | 51.9% vs 24.3%+27.6 vs placeboNCT010877883 other results
|
| ACR50 | —Not posted · NCT00646178 | —Not reported |
| PASI 75 | —Not posted · NCT00646178 | 60.5% vs 15.1%+45.4 vs placeboNCT010877881 other result
|
| Minimal disease activity | 41.5% vs 13.1%vs MTXNCT028141757 other results
| —Not reported |
| HAQ-DI, change | -0.5 vs -0.3vs MTXNCT02814175 | -0.5 vs -0.2−0.3 vs placeboNCT010877881 other result
|
ACR20
- adalimumab
- —Not posted · NCT00646178
- certolizumab pegol
- 51.9% vs 24.3%+27.6 vs placeboNCT01087788
3 other results
- 58% vs 24.3% NCT01087788
- 56.3% vs 23.5% NCT01087788
- 63.8% vs 23.5% NCT01087788
ACR50
- adalimumab
- —Not posted · NCT00646178
- certolizumab pegol
- —Not reported
PASI 75
- adalimumab
- —Not posted · NCT00646178
- certolizumab pegol
- 60.5% vs 15.1%+45.4 vs placeboNCT01087788
1 other result
- 62.2% vs 15.1% NCT01087788
Minimal disease activity
- adalimumab
- 41.5% vs 13.1%vs MTXNCT02814175
7 other results
- 53.8% vs 52.4% NCT03739853
- 46.2% vs 36.5% NCT03739853
- 54.9% vs 66.7% NCT02814175
- 80.4% vs 66.7% NCT02814175
- 29.8% vs 66.7% NCT02814175
- 55.4% vs 57.1% NCT03739853
- 64.6% vs 63.5% NCT03739853
- certolizumab pegol
- —Not reported
HAQ-DI, change
- adalimumab
- -0.5 vs -0.3vs MTXNCT02814175
- certolizumab pegol
- -0.5 vs -0.2−0.3 vs placeboNCT01087788
1 other result
- -0.5 vs -0.2 NCT01087788
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab: 4 of 4 rows · certolizumab pegol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab | certolizumab pegol |
|---|---|---|
| Dropout rate | 4.6%a NCT03739853 · Phase 4 · registry result, not featured evidence show 4 more results4.9%Part 1: ADA + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination —Part 2: ADA NCT02814175 · Phase 4 · registry result, not featured evidence —Part 2: ADA + MTX Escalated Dose NCT02814175 · Phase 4 · registry result, not featured evidence · combination —Part 2: ADA ew + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination | —400 mg Q4Wb NCT01087788 · Phase 3 show 6 more results—200 mg Q2W NCT01087788 · Phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT03739853 · Phase 4 · registry result, not featured evidence show 4 more results2.4%Part 1: ADA + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination —Part 2: ADA NCT02814175 · Phase 4 · registry result, not featured evidence —Part 2: ADA + MTX Escalated Dose NCT02814175 · Phase 4 · registry result, not featured evidence · combination —Part 2: ADA ew + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination | —400 mg Q4Wb NCT01087788 · Phase 3 show 6 more results—200 mg Q2W NCT01087788 · Phase 3 —Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 —Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 3.1%a NCT03739853 · Phase 4 · registry result, not featured evidence show 4 more results1.6%Part 1: ADA + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination 1.9%Part 2: ADA NCT02814175 · Phase 4 · registry result, not featured evidence 3.2%Part 2: ADA + MTX Escalated Dose NCT02814175 · Phase 4 · registry result, not featured evidence · combination 4.8%Part 2: ADA ew + MTX NCT02814175 · Phase 4 · registry result, not featured evidence · combination | 26.2%400 mg Q4Wb NCT01087788 · Phase 3 show 6 more results24.7%200 mg Q2W NCT01087788 · Phase 3 0%Q2W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 0%Q4W NCT03357471 · Phase 3 · registry result, not featured evidence · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 20%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 26.7%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence —400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a liver function test abnormalities 27.7% nausea 23.1% diarrhoea 9.2% NCT03739853 · Phase 4 · registry result, not featured evidence show 4 more resultsheadache 8.1% upper respiratory tract infection 8.1% cough 5.7% NCT02814175 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 3.7% alanine aminotransferase increased 1.9% back pain 1.9% NCT02814175 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 13.7% nasopharyngitis 6.3% nausea 4.2% NCT02814175 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 14.3% back pain 6.3% psoriatic arthropathy 6.3% NCT02814175 · Phase 4 · registry result, not featured evidence · combination | 400 mg Q4Wb upper respiratory tract infection 25.1% nasopharyngitis 21.5% pharyngitis 13.8% NCT01087788 · Phase 3 show 3 more results200 mg Q2W nasopharyngitis 22.7% upper respiratory tract infection 22.2% hypertension 15.2% NCT01087788 · Phase 3 400 mg Q4W influenza 40% cystitis 20% foetal vascular malperfusion 20% NCT04163016 · Phase 1 · registry result, not featured evidence 200 mg Q2W covid-19 40% headache 20% hypertension 13.3% NCT04163016 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 1 more result
show 7 more results
show 3 more results
+ 6 further endpoints in the CSV export.
certolizumab pegol
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Psoriasis
Shared mechanism: TNF-alpha · full Psoriasis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00195676 · Phase 3 · completed
Eligibility for this study required prior participation in an earlier adalimumab psoriasis trial, making this an open-label continuation rather than a fresh, independently controlled study. Within the retreatment group, 76.5% of patients regained clear or minimal skin at 16 weeks, but with no placebo or comparison arm in this phase, that rate cannot be attributed to the drug with the same confidence as a controlled trial.
Next expected readout: April 2028 · NCT07529925 (registry estimate)
Reported efficacy
Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed) (not_applicable)
Result source: NCT00195676
certolizumab pegol · Cimzia
Marketed by UCB
NCT02326272 · Phase 3 · completed
This was a randomized, double-blind (quadruple-masked), placebo-controlled trial in 227 adults with moderate-to-severe plaque psoriasis. Both the 200 mg and 400 mg certolizumab pegol doses produced significantly higher rates of skin clearance (PASI75: 81.4% and 82.6% vs 11.6% placebo) and physician-assessed clearance (66.8% and 71.6% vs 2.0% placebo) at week 16, both p<0.0001.
Next expected readout: June 2030 · NCT07352566 (registry estimate)
Reported efficacy
Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 16; Proportion of Subjects Who Achieve a Physician's Global Assessment (PGA) Clear or Almost Clear (With at Least 2-category Improvement) Response at Week 16: PASI 75 at Week 16 (CIMPASI-1): certolizumab pegol 200mg Q2W 66.5%, 400mg Q2W 75.8%, placebo 6.5% (P<0.0001 for both doses vs placebo). (met)
Result source: NCT02326298
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | certolizumab pegol |
|---|---|---|
| PASI 75 | 77.8% vs 11.5%+66.3 vs placeboNCT016460737 other results
| 82.6% vs 11.6%+71 vs placeboNCT0232627211 other results
|
| PASI 90 | 61.8% vs 54.2%vs EU RPPNCT025813453 other results
| 55.4% vs 4.5%+50.9 vs placeboNCT0232627211 other results
|
| PASI 100 | 18.4% vs 2.7%vs MethotrexateNCT012516142 other results
| —Not posted · NCT04123795 |
| sPGA 0/1 | 60.5% vs 40.5%vs MethotrexateNCT0125161411 other results
| 57.9% vs 4.2%+53.7 vs placeboNCT023262985 other results
|
| DLQI, change | -4.8 vs -4.2−0.6 vs placeboNCT007357873 other results
| -10 vs -3.8−6.2 vs placeboNCT023262725 other results
|
PASI 75
- adalimumab
- 77.8% vs 11.5%+66.3 vs placeboNCT01646073
7 other results
- 80.1% vs 79% NCT02581345
- 57.9% vs 32.4% NCT01251614
- 43.6% vs 32.4% NCT01251614
- 45.3% vs 2.3% NCT01646073
- 9.8% vs 0% NCT01646073
- 30.6% vs 8.7% NCT00735787
- 67% vs 27% NCT00932113
- certolizumab pegol
- 82.6% vs 11.6%+71 vs placeboNCT02326272
11 other results
- 75.8% vs 6.5% NCT02326298
- 66.7% vs 5% NCT02346240
- 87.1% vs 7.9% NCT03051217
- 81.4% vs 11.6% NCT02326272
- 66.5% vs 6.5% NCT02326298
- 61.3% vs 5% NCT02346240
- 73% vs 7.9% NCT03051217
- 74.7% vs 3.8% NCT02346240
- 68.2% vs 3.8% NCT02346240
- 82.8% vs 6.8% NCT00245765
- 74.6% vs 6.8% NCT00245765
PASI 90
- adalimumab
- 61.8% vs 54.2%vs EU RPPNCT02581345
3 other results
- 28.9% vs 21.6% NCT01251614
- 30.8% vs 21.6% NCT01251614
- 20.4% vs 0% NCT00735787
- certolizumab pegol
- 55.4% vs 4.5%+50.9 vs placeboNCT02326272
11 other results
- 43.6% vs 0.4% NCT02326298
- 49.1% vs 0.3% NCT02346240
- 34% vs 0.2% NCT02346240
- 75.7% vs 0.2% NCT03051217
- 52.6% vs 4.5% NCT02326272
- 35.8% vs 0.4% NCT02326298
- 39.8% vs 0.3% NCT02346240
- 31.2% vs 0.2% NCT02346240
- 53.8% vs 0.2% NCT03051217
- 46.6% vs 1.7% NCT00245765
- 39% vs 1.7% NCT00245765
PASI 100
- adalimumab
- 18.4% vs 2.7%vs MethotrexateNCT01251614
2 other results
- 10.3% vs 2.7% NCT01251614
- 14.3% vs 0% NCT00735787
- certolizumab pegol
- —Not posted · NCT04123795
sPGA 0/1
- adalimumab
- 60.5% vs 40.5%vs MethotrexateNCT01251614
11 other results
- 41% vs 40.5% NCT01251614
- 80.5% vs 14.9% NCT01646073
- 57.4% vs 4.6% NCT01646073
- 20.1% vs 0% NCT01646073
- 68.9% vs 66.1% NCT02581345
- 30.6% vs 4.3% NCT00735787
- 28.6% vs 13% NCT00735787
- 24.5% vs 8.7% NCT00735787
- 20.4% vs 4.3% NCT00735787
- 8.2% vs 4.3% NCT00735787
- 73% vs 27% NCT00932113
- certolizumab pegol
- 57.9% vs 4.2%+53.7 vs placeboNCT02326298
5 other results
- 47% vs 4.2% NCT02326298
- 66.7% vs 0% NCT03051217
- 52.7% vs 0% NCT03051217
- 72.4% vs 1.7% NCT00245765
- 52.5% vs 1.7% NCT00245765
DLQI, change
- adalimumab
- -4.8 vs -4.2−0.6 vs placeboNCT00735787
3 other results
- -7.9 vs -3.7 NCT01553058
- -4.1 vs -3.1 NCT00735787
- -4.3 vs -3.4 NCT00735787
- certolizumab pegol
- -10 vs -3.8−6.2 vs placeboNCT02326272
5 other results
- -10.2 vs -3.3 NCT02326298
- -6.8 vs -0.3 NCT03051217
- -10.4 vs -3.8 NCT02326272
- -9.3 vs -3.3 NCT02326298
- -6.8 vs -0.3 NCT03051217
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. adalimumab: 11 of 11 rows · certolizumab pegol: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | certolizumab pegol Rows use multiple source trials |
|---|---|---|
| BSA Involvement absolute value · percentage points Induction | 5.9% (n=15) vs 10.7% (n=15) Methotrexate (MTX) @ 16wka,b,c,d NCT00932113 · Phase 4 · registry result, not featured evidence | 5.6% (n=54) vs 28.8% (n=40) placebo @ 12wk400 mge,a,b,c,d NCT00245765 · Phase 2 · registry result, not featured evidence show 1 more dose7.1% (n=53) vs 28.8% (n=40) placebo @ 12wk200 mg NCT00245765 · Phase 2 · registry result, not featured evidence |
| PASI percent change · % of baseline No placebo or comparator arm | -81.74% (n=50) @ 12wka,b,c NCT01644396 · Phase 4 · registry result, not featured evidence 1 other source trial-45% (n=10) @ 12wk NCT02533375 · Phase 3 · registry result, not featured evidence | 90.6% (n=37) @ 12wk400 mge,a,b,c NCT00329303 · Phase 2 · registry result, not featured evidence show 7 more doses91.78% (n=35) @ 12wk400 mg NCT00329303 · Phase 2 · registry result, not featured evidence 87.94% (n=37)400 mg NCT00329303 · Phase 2 · registry result, not featured evidence 87.59% (n=35) @ 12wk400 mg NCT00329303 · Phase 2 · registry result, not featured evidence 92.45% (n=34) @ 12wk200 mg NCT00329303 · Phase 2 · registry result, not featured evidence 84.11% (n=32) @ 12wk200 mg NCT00329303 · Phase 2 · registry result, not featured evidence 83.46% (n=34)200 mg NCT00329303 · Phase 2 · registry result, not featured evidence 78.75% (n=32) @ 12wk200 mg NCT00329303 · Phase 2 · registry result, not featured evidence |
| PASI 50 responder rate · % of participants Induction | 42.9% (n=49) vs 21.7% (n=23) placebo @ 16wk*a,b,c,d NCT00735787 · Phase 4 · registry result, not featured evidence · converted to % from 21 subjects as posted 1 other source trial91% (n=267) vs 93.4% (n=271) EU RPP @ 16wk* NCT02581345 · Phase 3 · registry result, not featured evidence · converted to % from 243 Participants as posted | 93.1% (n=58) vs 11.9% (n=59) placebo @ 12wk400 mge,a,b,c,d NCT00245765 · Phase 2 · registry result, not featured evidence show 1 more dose86.4% (n=59) vs 11.9% (n=59) placebo @ 12wk200 mg NCT00245765 · Phase 2 · registry result, not featured evidence |
| PASI 50 responder rate · % of participants No placebo or comparator arm | 88% (n=50) @ 12wka,b,c NCT01644396 · Phase 4 · registry result, not featured evidence 3 other source trials50% (n=10) @ 12wk* NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted 87.6% (n=89) @ 12wk*40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 78 Participants as posted 93.1% (n=58) @ 12wk*80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 54 Participants as posted | 89.2% (n=37) @ 12wk400 mge,a,b,c NCT00329303 · Phase 2 · registry result, not featured evidence show 3 more doses89.2% (n=37) @ 12wk400 mg NCT00329303 · Phase 2 · registry result, not featured evidence 76.5% (n=34) @ 12wk200 mg NCT00329303 · Phase 2 · registry result, not featured evidence 67.6% (n=34) @ 12wk200 mg NCT00329303 · Phase 2 · registry result, not featured evidence |
| PASI 75 responder rate · % of participants No placebo or comparator arm | 76% (n=50) @ 12wka,b,c NCT01644396 · Phase 4 · registry result, not featured evidence 3 other source trials20% (n=10) @ 12wk* NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted 60.7% (n=89) @ 12wk*40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 54 Participants as posted 77.6% (n=58) @ 12wk*80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 45 Participants as posted | 86.5% (n=37) @ 12wk400 mge,a,b,c NCT00329303 · Phase 2 · registry result, not featured evidence show 3 more doses75.7% (n=37) @ 12wk400 mg NCT00329303 · Phase 2 · registry result, not featured evidence 67.6% (n=34) @ 12wk200 mg NCT00329303 · Phase 2 · registry result, not featured evidence 50% (n=34) @ 12wk200 mg NCT00329303 · Phase 2 · registry result, not featured evidence |
| PASI 90 responder rate · % of participants No placebo or comparator arm | 48% (n=50) @ 12wka,b,c NCT01644396 · Phase 4 · registry result, not featured evidence 3 other source trials10% (n=10) @ 12wk* NCT02533375 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted 34.8% (n=89) @ 12wk*40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 31 Participants as posted 50% (n=58) @ 12wk*80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence · converted to % from 29 Participants as posted | 48.6% (n=37) @ 12wk400 mge,a,b,c NCT00329303 · Phase 2 · registry result, not featured evidence show 3 more doses40.5% (n=37) @ 12wk400 mg NCT00329303 · Phase 2 · registry result, not featured evidence 35.3% (n=34) @ 12wk200 mg NCT00329303 · Phase 2 · registry result, not featured evidence 29.4% (n=34) @ 12wk200 mg NCT00329303 · Phase 2 · registry result, not featured evidence |
| sPGA 0/1 responder rate · % of participants No placebo or comparator arm | 72% (n=50) @ 12wka,b,c NCT01644396 · Phase 4 · registry result, not featured evidence 4 other source trials34% (n=50) @ 12wk* NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 17 Participants as posted 31.4% (n=35) @ 12wk* NCT00927069 · Phase 3 · registry result, not featured evidence · converted to % from 11 Participants as posted 50% (n=366) @ 12wk NCT00574249 · Phase 3 · registry result, not featured evidence · combination 64.8% (n=364) @ 12wk NCT00574249 · Phase 3 · registry result, not featured evidence | 56.8% (n=37) @ 12wk400 mge,a,b,c NCT00329303 · Phase 2 · registry result, not featured evidence show 1 more dose52.9% (n=34) @ 12wk200 mg NCT00329303 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 41.3%f NCT00195676 · Phase 3 show 35 more results6.7% NCT00932113 · Phase 4 · registry result, not featured evidence 3% NCT01553058 · Phase 4 · registry result, not featured evidence 0% NCT01644396 · Phase 4 · registry result, not featured evidence 4.7% NCT01265823 · Phase 4 · registry result, not featured evidence 16.3% NCT00735787 · Phase 4 · registry result, not featured evidence 9.4% NCT05637515 · Phase 3 · registry result, not featured evidence 50% NCT02533375 · Phase 3 · registry result, not featured evidence 5.2%Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 13.8%EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 21.1%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 33.3%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 1.5%Eow NCT01646073 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 11%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 4.9%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 17.2%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence 2%Group A NCT00927069 · Phase 3 · registry result, not featured evidence 2.9%Group B NCT00927069 · Phase 3 · registry result, not featured evidence 7.7%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 7.1%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence 11.8%40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence 22.4%80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 24.7%40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 0% NCT01872546 · Phase 2 · registry result, not featured evidence 11.1% NCT01320293 · Phase na · registry result, not featured evidence | —400 mg Q2Wf NCT02326272 · Phase 3 show 20 more results—200 mg Q2W NCT02326272 · Phase 3 —400 mg Q2W NCT02326298 · Phase 3 —200 mg Q2W NCT02326298 · Phase 3 —400 mg Q2W NCT02346240 · Phase 3 —400 mg Q4W NCT02346240 · Phase 3 —200 mg Q2W NCT02346240 · Phase 3 —400 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence —400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence —200 mg Q2W + 400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination —200 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence —All CZP (SS) NCT03051217 · Phase 2/3 · registry result, not featured evidence 5.4%400 mg NCT00329303 · Phase 2 · registry result, not featured evidence 5.9%200 mg NCT00329303 · Phase 2 · registry result, not featured evidence 13.8%400 mg NCT00245765 · Phase 2 · registry result, not featured evidence —400 mg NCT00245765 · Phase 2 · registry result, not featured evidence 23.7%200 mg NCT00245765 · Phase 2 · registry result, not featured evidence —200 mg NCT00245765 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 5.6%f NCT00195676 · Phase 3 show 35 more results— NCT00932113 · Phase 4 · registry result, not featured evidence — NCT01553058 · Phase 4 · registry result, not featured evidence — NCT01644396 · Phase 4 · registry result, not featured evidence — NCT01265823 · Phase 4 · registry result, not featured evidence — NCT00735787 · Phase 4 · registry result, not featured evidence — NCT05637515 · Phase 3 · registry result, not featured evidence 20% NCT02533375 · Phase 3 · registry result, not featured evidence 1%Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 4.6%EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 2.6%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0.6%Eow NCT01646073 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 6.9%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —Group A NCT00927069 · Phase 3 · registry result, not featured evidence —Group B NCT00927069 · Phase 3 · registry result, not featured evidence 4.9%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 1.6%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence —40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence —80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence —40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence — NCT01872546 · Phase 2 · registry result, not featured evidence 5.6% NCT01320293 · Phase na · registry result, not featured evidence | —400 mg Q2Wf NCT02326272 · Phase 3 show 20 more results—200 mg Q2W NCT02326272 · Phase 3 —400 mg Q2W NCT02326298 · Phase 3 —200 mg Q2W NCT02326298 · Phase 3 —400 mg Q2W NCT02346240 · Phase 3 —400 mg Q4W NCT02346240 · Phase 3 —200 mg Q2W NCT02346240 · Phase 3 —400 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence —400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence —200 mg Q2W + 400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination —200 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence —All CZP (SS) NCT03051217 · Phase 2/3 · registry result, not featured evidence —400 mg NCT00329303 · Phase 2 · registry result, not featured evidence —200 mg NCT00329303 · Phase 2 · registry result, not featured evidence 0%400 mg NCT00245765 · Phase 2 · registry result, not featured evidence —400 mg NCT00245765 · Phase 2 · registry result, not featured evidence 1.7%200 mg NCT00245765 · Phase 2 · registry result, not featured evidence —200 mg NCT00245765 · Phase 2 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 12.9%f NCT00195676 · Phase 3 show 35 more results0% NCT00932113 · Phase 4 · registry result, not featured evidence 6.1% NCT01553058 · Phase 4 · registry result, not featured evidence 0% NCT01644396 · Phase 4 · registry result, not featured evidence 0.7% NCT01265823 · Phase 4 · registry result, not featured evidence 4.1% NCT00735787 · Phase 4 · registry result, not featured evidence 1.7% NCT05637515 · Phase 3 · registry result, not featured evidence 30% NCT02533375 · Phase 3 · registry result, not featured evidence —Part 1 and Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 1.4%Part 1: M923 NCT02581345 · Phase 3 · registry result, not featured evidence 3.7%Part 2: M923 NCT02581345 · Phase 3 · registry result, not featured evidence —EOW NCT02016482 · Phase 3 · registry result, not featured evidence 7.3%EOW NCT02016482 · Phase 3 · registry result, not featured evidence 3.2%EOW NCT02016482 · Phase 3 · registry result, not featured evidence 0%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 5.7%0.8 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 7.7%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence 0%0.4 mg/kg NCT01251614 · Phase 3 · registry result, not featured evidence —Eow NCT01646073 · Phase 3 · registry result, not featured evidence 1.2%Eow NCT01646073 · Phase 3 · registry result, not featured evidence 4.9%Sub-optimal Response to Etanercept NCT00566722 · Phase 3 · registry result, not featured evidence 0%Sub-optimal Response to MTX NCT00566722 · Phase 3 · registry result, not featured evidence 3.4%Sub-optimal Response to Narrow-ban NCT00566722 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence —40 mg every week NCT00927069 · Phase 3 · registry result, not featured evidence 0%Group A NCT00927069 · Phase 3 · registry result, not featured evidence 0%Group B NCT00927069 · Phase 3 · registry result, not featured evidence 4.4%Adalimumab + Calcipotriol/Betameth NCT00574249 · Phase 3 · registry result, not featured evidence · combination 4.1%Adalimumab + Placebo NCT00574249 · Phase 3 · registry result, not featured evidence —40 mg Eow NCT00513370 · Phase 3 · registry result, not featured evidence 19%80 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 21.3%40 mg every other week NCT00647400 · Phase 2/3 · registry result, not featured evidence 0% NCT01872546 · Phase 2 · registry result, not featured evidence 5.6% NCT01320293 · Phase na · registry result, not featured evidence | 8.1%400 mg Q2Wf NCT02326272 · Phase 3 show 20 more results14.1%200 mg Q2W NCT02326272 · Phase 3 11.4%400 mg Q2W NCT02326298 · Phase 3 7.4%200 mg Q2W NCT02326298 · Phase 3 12.4%400 mg Q2W NCT02346240 · Phase 3 11.4%400 mg Q4W NCT02346240 · Phase 3 9.1%200 mg Q2W NCT02346240 · Phase 3 9.4%400 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence 0%400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence 2.8%200 mg Q2W + 400 mg Q4W NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination 2.8%200 mg Q2W NCT03051217 · Phase 2/3 · registry result, not featured evidence 6.6%All CZP (SS) NCT03051217 · Phase 2/3 · registry result, not featured evidence 0%400 mg NCT00329303 · Phase 2 · registry result, not featured evidence 0%200 mg NCT00329303 · Phase 2 · registry result, not featured evidence —400 mg NCT00245765 · Phase 2 · registry result, not featured evidence 8.8%400 mg NCT00245765 · Phase 2 · registry result, not featured evidence —200 mg NCT00245765 · Phase 2 · registry result, not featured evidence 3.3%200 mg NCT00245765 · Phase 2 · registry result, not featured evidence —400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 20%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 26.7%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | show 29 more resultsupper respiratory tract infection 40% dizziness 13.3% flu-like symptoms 13.3% NCT00932113 · Phase 4 · registry result, not featured evidence upper respiratory infection 9.1% (placebo 12.9%) joint range of motion decrease 6.1% (placebo 0%) headache 3% (placebo 6.5%) NCT01553058 · Phase 4 · registry result, not featured evidence latent tuberculosis 8% rhinitis 6% alanine aminotransferase increased 2% NCT01644396 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 11.3% hyperglycemia 10.7% arthralgia 6.7% NCT01265823 · Phase 4 · registry result, not featured evidence nasopharyngitis 26.5% (placebo 13%) headache 14.3% (placebo 4.3%) cough 8.2% (placebo 4.3%) NCT00735787 · Phase 4 · registry result, not featured evidence headache 2.2% nasopharyngitis 2.2% upper respiratory tract infection 2.2% NCT05637515 · Phase 3 · registry result, not featured evidence nasopharyngitis 30% pruritus 30% hypoalbuminaemia 20% NCT02533375 · Phase 3 · registry result, not featured evidence injection site reaction 23.9% nasopharyngitis 6.7% headache 3.2% NCT02581345 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.8% psoriasis 10.3% injection site reaction 10% NCT02581345 · Phase 3 · registry result, not featured evidence EOW upper respiratory tract infection 8.3% (placebo 8.3%) headache 5.5% (placebo 0%) nasopharyngitis 5.5% (placebo 9.3%) NCT02016482 · Phase 3 · registry result, not featured evidence EOW nasopharyngitis 12.8% (placebo 9.3%) upper respiratory tract infection 4.3% (placebo 8.3%) depression 3.2% (placebo 0.9%) NCT02016482 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 21.1% headache 15.8% dry skin 7.9% NCT01251614 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 18.5% back pain 11.1% headache 11.1% NCT01251614 · Phase 3 · registry result, not featured evidence 0.8 mg/kg nasopharyngitis 28.7% headache 25.3% upper respiratory tract infection 14.9% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg nasopharyngitis 25.6% headache 17.9% cough 10.3% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg cough 18.2% decreased appetite 9.1% gastroenteritis 9.1% NCT01251614 · Phase 3 · registry result, not featured evidence 0.4 mg/kg nasopharyngitis 23.1% agitation 7.7% cough 7.7% NCT01251614 · Phase 3 · registry result, not featured evidence Eow upper respiratory tract infection 10.1% (placebo 6.9%) oropharyngeal pain 4.1% (placebo 1.1%) nasopharyngitis 3.8% (placebo 5.7%) NCT01646073 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 6.1% cough 3.7% headache 3.7% NCT00566722 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 12.2% injection site erythema 7.3% nasopharyngitis 7.3% NCT00566722 · Phase 3 · registry result, not featured evidence fatigue 6.9% pharyngitis 6.9% abdominal pain 3.4% NCT00566722 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 18% back pain 8% common cold 8% NCT00927069 · Phase 3 · registry result, not featured evidence headache 11.4% common cold 5.7% upper respiratory tract infection 5.7% NCT00927069 · Phase 3 · registry result, not featured evidence nasopharyngitis 8.7% headache 5.2% psoriasis 5.2% NCT00574249 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 6.3% headache 6% pruritus 5.8% NCT00574249 · Phase 3 · registry result, not featured evidence 40 mg Eow nasopharyngitis 10.8% upper respiratory tract infection 10.8% headache 4.9% NCT00513370 · Phase 3 · registry result, not featured evidence 80 mg every other week nasopharyngitis 77.6% blood triglycerides increased 29.3% blood creatine phosphokinase increased 25.9% NCT00647400 · Phase 2/3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 75.3% blood triglycerides increased 24.7% alanine aminotransferase increased 23.6% NCT00647400 · Phase 2/3 · registry result, not featured evidence upper respiratory tract infection 22.2% elbow strain 5.6% heartburn 5.6% NCT01320293 · Phase na · registry result, not featured evidence | 400 mg Q2Wf nasopharyngitis 23.5% upper respiratory tract infection 12.1% psoriasis 8.1% NCT02326272 · Phase 3 show 17 more results200 mg Q2W nasopharyngitis 19.4% upper respiratory tract infection 11.2% sinusitis 7.6% NCT02326272 · Phase 3 400 mg Q2W nasopharyngitis 30.5% upper respiratory tract infection 15.6% headache 8.4% NCT02326298 · Phase 3 200 mg Q2W nasopharyngitis 28.7% upper respiratory tract infection 11.2% arthralgia 7.4% NCT02326298 · Phase 3 400 mg Q2W nasopharyngitis 16% (placebo 11.7%) upper respiratory tract infection 10.9% (placebo 10.2%) hypertension 5.8% (placebo 5.5%) NCT02346240 · Phase 3 400 mg Q4W arthralgia 6.8% (placebo 2.3%) blood creatine phosphokinase increased 6.8% (placebo 1.6%) nasopharyngitis 6.8% (placebo 11.7%) NCT02346240 · Phase 3 200 mg Q2W nasopharyngitis 15% (placebo 11.7%) upper respiratory tract infection 10.2% (placebo 10.2%) viral upper respiratory tract infection 6.2% (placebo 1.6%) NCT02346240 · Phase 3 400 mg Q2W nasopharyngitis 43.8% (placebo 23.1%) psoriasis 7.8% (placebo 23.1%) dermatitis contact 6.3% (placebo 0%) NCT03051217 · Phase 2/3 · registry result, not featured evidence 400 mg Q4W nasopharyngitis 30% (placebo 23.1%) back pain 10% (placebo 0%) dental caries 10% (placebo 0%) NCT03051217 · Phase 2/3 · registry result, not featured evidence 200 mg Q2W + 400 mg Q4W nasopharyngitis 34.7% (placebo 23.1%) psoriasis 11.1% (placebo 23.1%) eczema 6.9% (placebo 0%) NCT03051217 · Phase 2/3 · registry result, not featured evidence · combination 200 mg Q2W nasopharyngitis 31.9% (placebo 23.1%) psoriasis 11.1% (placebo 23.1%) eczema 6.9% (placebo 0%) NCT03051217 · Phase 2/3 · registry result, not featured evidence nasopharyngitis 43.4% (placebo 23.1%) psoriasis 10.7% (placebo 23.1%) eczema 7.4% (placebo 0%) NCT03051217 · Phase 2/3 · registry result, not featured evidence 400 mg headache 8.1% nasopharyngitis 8.1% asthenia 5.4% NCT00329303 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 14.7% psoriasis 11.8% arthralgia 5.9% NCT00329303 · Phase 2 · registry result, not featured evidence 400 mg nasopharyngitis 21.1% (placebo 17.2%) headache 14% (placebo 15.5%) bronchitis 7% (placebo 5.2%) NCT00245765 · Phase 2 · registry result, not featured evidence 200 mg headache 21.7% (placebo 15.5%) pruritus 11.7% (placebo 6.9%) arthralgia 8.3% (placebo 3.4%) NCT00245765 · Phase 2 · registry result, not featured evidence 400 mg Q4W influenza 40% cystitis 20% foetal vascular malperfusion 20% NCT04163016 · Phase 1 · registry result, not featured evidence 200 mg Q2W covid-19 40% headache 20% hypertension 13.3% NCT04163016 · Phase 1 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 16 weeks versus 12 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 11 more results
show 5 more results
show 7 more results
show 12 more results
show 2 more results
show 1 more result
+ 169 further endpoints in the CSV export.
certolizumab pegol
show 1 more result
show 1 more result
show 3 more results
show 4 more results
show 1 more result
show 29 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00195702 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).
Next expected readout: December 2027 · NCT06440629 (registry estimate)
Reported efficacy
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24; Change From Baseline in Modified Total Sharp X-ray Score at Week 52 (Baseline and Week 52); Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52 (Baseline and Week 52): Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. (met)
Result source: NCT00195702
certolizumab pegol · Cimzia
Marketed by UCB
NCT03357471 · Phase 3 · completed
Allocation was NON_RANDOMIZED with masking NONE and no control/comparator arm (two parallel non-randomized dosing groups, not randomized treatment vs. control), so this defaults to 'weak' per the design test regardless of the very high reported success rates; the primary endpoint is also a device-usability surrogate rather than a hard clinical/endoscopic outcome.
Next expected readout: March 2028 · NCT03414502 (registry estimate)
Reported efficacy
Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2 (Visit 2 (Week 2 for Q2W; Week 4 for Q4W)): Certolizumab Pegol Q2W Injection by e-Device (SS) 100 percentage of subjects (95% CI 91.3 to 100) | Certolizumab Pegol Q4W Injection by e-Device (SS) 96.88 percentage of subjects (95% CI 86 to 99.8)
Result source: NCT03357471
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | certolizumab pegol |
|---|---|---|
| ACR20 | 63.3% vs 29.5%+33.8 vs placeboNCT0019570228 other results
| 54.8% vs 23.9%+30.9 vs placeboNCT0215185121 other results
|
| ACR50 | 41.2% vs 45.9%vs MethotrexateNCT0019566319 other results
| 61.8% vs 52.6%+9.2 vs placeboNCT0151979111 other results
|
| ACR70 | 47.4% vs 22.7%+24.7 vs placeboNCT0087046716 other results
| 51.3% vs 39.9%+11.4 vs placeboNCT015197919 other results
|
| DAS28-CRP remission | 38.5% vs 42.9%vs Standard of CareNCT011624215 other results
| 16% vs 5.7%+10.3 vs placeboNCT00717236 |
| HAQ-DI, change | -0.6 vs -0.3−0.3 vs placeboNCT0019570222 other results
| -1.0 vs -0.8−0.2 vs placeboNCT015197918 other results
|
| Modified Sharp score, change | 0.1 vs 2.7−2.6 vs placeboNCT0019570215 other results
| 0.4 vs 1.6−1.2 vs placeboNCT014512036 other results
|
ACR20
- adalimumab
- 63.3% vs 29.5%+33.8 vs placeboNCT00195702
28 other results
- 50.3% vs 33.9% NCT00647270
- 57% vs 35% NCT00538902
- 47.3% vs 33.9% NCT00647270
- 51.2% vs 35% NCT00538902
- 60.8% vs 29.5% NCT00195702
- 58.9% vs 24% NCT00195702
- 54.7% vs 24% NCT00195702
- 75.4% vs 56.4% NCT00870467
- 49.3% vs 56% NCT00195663
- 69.4% vs 56% NCT00195663
- 50% vs 59.9% NCT00195663
- 69% vs 59.9% NCT00195663
- 54.4% vs 62.6% NCT00195663
- 72.8% vs 62.6% NCT00195663
- 53.3% vs 61.5% NCT00195663
- 68.7% vs 61.5% NCT00195663
- 69.2% vs 71.4% NCT01500278
- 84.8% vs 80.4% NCT00420927
- 66.4% vs 80.4% NCT00420927
- 64.5% vs 60.8% NCT01500278
- 68% vs 68% NCT01712178
- 62% vs 68% NCT01712178
- 46.2% vs 65.7% NCT01162421
- 51.3% vs 65.7% NCT01162421
- 56.4% vs 68.6% NCT01162421
- 66.7% vs 60% NCT01162421
- 64.1% vs 37.1% NCT01162421
- 69.2% vs 57.1% NCT01162421
- certolizumab pegol
- 54.8% vs 23.9%+30.9 vs placeboNCT02151851
21 other results
- 51.1% vs 25.9% NCT00717236
- 77.6% vs 28.6% NCT00791999
- 67.2% vs 14.9% NCT00791921
- 76.8% vs 28.6% NCT00791999
- 62.5% vs 28.6% NCT00791999
- 66.7% vs 27.5% NCT00993317
- 69% vs 61.5% NCT01519791
- 71.8% vs 24.7% NCT00791999
- 36.5% vs 15.3% NCT00674362
- 63.8% vs 11.4% NCT00791921
- 73.2% vs 24.7% NCT00791999
- 61.1% vs 24.7% NCT00791999
- 64.2% vs 37.5% NCT00993317
- 86.5% vs 74.7% NCT01521923
- 73.8% vs 74.7% NCT01521923
- 65.2% vs 44.9% NCT00580840
- 67.1% vs 44.9% NCT00580840
- 61.5% vs 0% NCT01147341
- 69.2% vs 71.4% NCT01500278
- 54.5% vs 62.5% NCT01147341
- 64.5% vs 60.8% NCT01500278
ACR50
- adalimumab
- 41.2% vs 45.9%vs MethotrexateNCT00195663
19 other results
- 61.6% vs 45.9% NCT00195663
- 64.3% vs 38.7% NCT00870467
- 36.9% vs 42.8% NCT00195663
- 59% vs 42.8% NCT00195663
- 41.6% vs 44.4% NCT00195663
- 60.1% vs 44.4% NCT00195663
- 35% vs 40.5% NCT00195663
- 58.6% vs 40.5% NCT00195663
- 78.1% vs 69.6% NCT00420927
- 46.3% vs 69.6% NCT00420927
- 48% vs 50% NCT01712178
- 36% vs 40% NCT01712178
- 33.3% vs 42.9% NCT01162421
- 38.5% vs 45.7% NCT01162421
- 43.6% vs 34.3% NCT01162421
- 48.7% vs 40% NCT01162421
- 43.6% vs 22.9% NCT01162421
- 38.5% vs 22.9% NCT01162421
- 64.7% vs 51.6% NCT03823391
- certolizumab pegol
- 61.8% vs 52.6%+9.2 vs placeboNCT01519791
11 other results
- 80.2% vs 68.4% NCT01521923
- 36.5% vs 7.1% NCT02151851
- 26.6% vs 9.9% NCT00717236
- 20.8% vs 7.1% NCT00674362
- 43.2% vs 20% NCT00993317
- 25.9% vs 12.5% NCT00993317
- 71.4% vs 68.4% NCT01521923
- 52.2% vs 30.4% NCT00580840
- 50% vs 30.4% NCT00580840
- 27.3% vs 37.5% NCT01147341
- 19.2% vs 0% NCT01147341
ACR70
- adalimumab
- 47.4% vs 22.7%+24.7 vs placeboNCT00870467
16 other results
- 28.1% vs 28.4% NCT00195663
- 46.6% vs 28.4% NCT00195663
- 28.8% vs 29.2% NCT00195663
- 47.4% vs 29.2% NCT00195663
- 25.9% vs 27.2% NCT00195663
- 45.5% vs 27.2% NCT00195663
- 19.7% vs 22.2% NCT00195663
- 42.5% vs 22.2% NCT00195663
- 69.5% vs 57.1% NCT00420927
- 30.1% vs 57.1% NCT00420927
- 23.1% vs 40% NCT01162421
- 30.8% vs 20% NCT01162421
- 30.8% vs 14.3% NCT01162421
- 25.6% vs 22.9% NCT01162421
- 28.2% vs 8.6% NCT01162421
- 15.4% vs 2.9% NCT01162421
- certolizumab pegol
- 51.3% vs 39.9%+11.4 vs placeboNCT01519791
9 other results
- 12.9% vs 2.8% NCT00717236
- 13.6% vs 0% NCT00993317
- 70.6% vs 60.8% NCT01521923
- 16.7% vs 2.7% NCT02151851
- 9.4% vs 3.1% NCT00674362
- 17.3% vs 2.5% NCT00993317
- 63.1% vs 60.8% NCT01521923
- 37.7% vs 15.9% NCT00580840
- 30% vs 15.9% NCT00580840
DAS28-CRP remission
- adalimumab
- 38.5% vs 42.9%vs Standard of CareNCT01162421
5 other results
- 30.8% vs 34.3% NCT01162421
- 35.9% vs 22.9% NCT01162421
- 28.2% vs 31.4% NCT01162421
- 35.9% vs 11.4% NCT01162421
- 17.9% vs 8.6% NCT01162421
- certolizumab pegol
- 16% vs 5.7%+10.3 vs placeboNCT00717236
HAQ-DI, change
- adalimumab
- -0.6 vs -0.3−0.3 vs placeboNCT00195702
22 other results
- -0.6 vs -0.3 NCT00195702
- -0.6 vs -0.2 NCT00195702
- -0.4 vs -0.1 NCT00647270
- -0.4 vs -0.1 NCT00647270
- -0.3 vs 0 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.5 vs -0.3 NCT00538902
- -0.4 vs -0.1 NCT00647270
- -0.4 vs -0.1 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.4 vs -0.3 NCT00538902
- -0.6 vs -0.2 NCT00195702
- -0.8 vs -0.8 NCT00195663
- -1.1 vs -0.8 NCT00195663
- -0.6 vs -0.7 NCT01500278
- -0.5 vs -0.6 NCT01162421
- -0.6 vs -0.6 NCT01162421
- -0.5 vs -0.6 NCT01162421
- -0.5 vs -0.5 NCT01162421
- -0.5 vs -0.3 NCT01162421
- -0.4 vs -0.4 NCT01162421
- certolizumab pegol
- -1.0 vs -0.8−0.2 vs placeboNCT01519791
8 other results
- -0.5 vs -0.2 NCT02151851
- -0.4 vs -0.2 NCT00717236
- -0.3 vs -0.0 NCT00674362
- -0.5 vs -0.2 NCT00993317
- -0.5 vs -0.8 NCT01235598
- -0.6 vs -0.4 NCT00580840
- -0.7 vs -0.4 NCT00580840
- -0.6 vs -0.7 NCT01500278
Modified Sharp score, change
- adalimumab
- 0.1 vs 2.7−2.6 vs placeboNCT00195702
15 other results
- 0.8 vs 2.7 NCT00195702
- 1.5 vs 2.4 NCT00870467
- 3 vs 5.7 NCT00195663
- 1.3 vs 5.7 NCT00195663
- 0.3 vs 1.3 NCT00195702
- 0.1 vs 4.8 NCT00195702
- 0.7 vs 6.2 NCT00195702
- 0.6 vs 1.3 NCT00195702
- 1.2 vs 4.8 NCT00195702
- 2.6 vs 6.2 NCT00195702
- 5.5 vs 10.4 NCT00195663
- 1.9 vs 10.4 NCT00195663
- 0.0 vs 2.2 NCT01162421
- 0.2 vs 1.6 NCT01162421
- 0.0 vs 0.9 NCT01162421
- certolizumab pegol
- 0.4 vs 1.6−1.2 vs placeboNCT01451203
6 other results
- 0.2 vs 1.8 NCT01519791
- 0 vs 0 NCT01521923
- 0 vs 0 NCT01521923
- 0 vs 0 NCT01521923
- 0 vs 0 NCT01521923
- 0.3 vs 0.9 NCT01451203
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
30 other shared endpoints and safety
Coverage. adalimumab: 34 of 34 rows · certolizumab pegol: 34 of 34 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | certolizumab pegol Rows use multiple source trials |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 97% (n=133) @ 52wk*a,b,c,d NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 129 participants as posted show 1 more dose80% (n=5) @ 52wk* NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 4 participants as posted | 81.3% (n=841)b,c,d NCT00175877 · Phase 3 8 other source trials83.3% (n=12) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 76.7% (n=43) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 90.7% (n=43) @ 52wk400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 70% (n=110) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 81.7% (n=493) @ 52wk NCT00160641 · Phase 3 · registry result, not featured evidence 74.2% (n=565) NCT00160641 · Phase 3 · registry result, not featured evidence 58.1% (n=370) @ 52wk NCT00160693 · Phase 3 · registry result, not featured evidence 57.2% (n=402) NCT00160693 · Phase 3 · registry result, not featured evidence |
| ACR50 responder rate · % of participants No placebo or comparator arm | 88% (n=133) @ 52wk*a,b,c,d NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 117 participants as posted show 1 more dose40% (n=5) @ 52wk* NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 2 participants as posted | 57.6% (n=841)b,c,d NCT00175877 · Phase 3 7 other source trials58.3% (n=12) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 62.8% (n=43) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 69.8% (n=43) @ 52wk400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 40.9% (n=110) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 48.9% (n=493) @ 52wk NCT00160641 · Phase 3 · registry result, not featured evidence 47.4% (n=565) NCT00160641 · Phase 3 · registry result, not featured evidence 27.6% (n=402) NCT00160693 · Phase 3 · registry result, not featured evidence |
| ACR70 responder rate · % of participants No placebo or comparator arm | 65.4% (n=133) @ 52wk*a,b,c,d NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted show 1 more dose0% (n=5) @ 52wk* NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 0 participants as posted | 38.2% (n=841)b,c,d NCT00175877 · Phase 3 7 other source trials16.7% (n=12) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 58.1% (n=43) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 46.5% (n=43) @ 52wk400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 22.7% (n=110) @ 52wk200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 26.2% (n=493) @ 52wk NCT00160641 · Phase 3 · registry result, not featured evidence 25.5% (n=565) NCT00160641 · Phase 3 · registry result, not featured evidence 7.7% (n=402) NCT00160693 · Phase 3 · registry result, not featured evidence |
| All-Cause Discontinuation event count · % of participants | 0.2635% (n=353) vs 0.2247% (n=361) ADA+MTX @ 104wkb NCT01500278 · Phase 4 · registry result, not featured evidence · combination | 0.2635% (n=353) vs 0.2247% (n=361) ADA+MTX @ 104wkb NCT01500278 · Phase 4 · registry result, not featured evidence · combination |
| CDAI absolute change · score | -26.3 vs -27.99 ABBV-3373 score @ 12wke,b,c NCT03823391 · Phase 2 · registry result, not featured evidence | -18.96 vs -10.93 placebo score @ 12wke,b,c NCT00717236 · Phase 3 · registry result, not featured evidence |
| CDAI Clinical Remission responder rate · % of participants | 55.2% (n=105) vs 48.2% (n=112) placebo @ 78wk*a,f,b,g NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted show 1 more dose15.1% (n=259) vs 48.2% (n=112) placebo @ 78wk* NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted | 52.4% (n=84) vs 43% (n=79) placebo @ 104wkQ2Wa,f,b,g NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 1 more dose55.6% (n=126) vs 43% (n=79) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination |
| CDAI Clinical Remission responder rate · % of participants No placebo or comparator arm | 27.6% (n=98) @ 26wk20 mg MTXa,b,c,h NCT01185301 · Phase 3 · registry result, not featured evidence · combination show 3 more doses29.3% (n=99) @ 26wk10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 22% (n=100) @ 26wk5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 12.2% (n=98) @ 26wk2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination | 27.9% (n=122) @ 136wkb,c,h NCT00843778 · Phase 3 · registry result, not featured evidence |
| CRP Change absolute change · mg | -11.2 vs -13.5 Standard of Care mg @ 104wkf,b,c,i NCT01162421 · Phase 4 · registry result, not featured evidence | 0.55 vs 1.05 placebo mg @ 12wkf,b,c,i NCT00717236 · Phase 3 · registry result, not featured evidence |
| DAS28 absolute change · score | -3.71 vs -3.04 placebo score @ 78wka,b,j NCT00420927 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-2.7 vs -3.04 placebo score @ 78wk NCT00420927 · Phase 4 · registry result, not featured evidence · combination | -3.04 vs -1.65 placebo score @ 34wk400 mga,b,j NCT00580840 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-2.83 vs -1.65 placebo score @ 34wk200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination |
| DAS28 Low Disease Activity responder rate · % of participants | 58.8% (n=17) vs 54.8% (n=31) ABBV-3373 @ 12wke,b,c,k NCT03823391 · Phase 2 · registry result, not featured evidence | 48.8% (n=84) vs 39.2% (n=79) placebo @ 104wkQ2Wa,e,b,c,k NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 5 more doses65.5% (n=84) vs 59.5% (n=79) placebo @ 104wkQ2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 70.2% (n=84) vs 68.4% (n=79) placebo @ 104wkQ2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 53.2% (n=126) vs 39.2% (n=79) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 73.8% (n=126) vs 59.5% (n=79) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 74.6% (n=126) vs 68.4% (n=79) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination |
| DAS28 Low Disease Activity responder rate · % of participants No placebo or comparator arm | 60.2% (n=98) @ 26wk20 mg MTXa,l,m,b,c,n NCT01185301 · Phase 3 · registry result, not featured evidence · combination show 3 more doses56.6% (n=99) @ 26wk10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 44% (n=100) @ 26wk5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 42.9% (n=98) @ 26wk2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination | 32.3% (n=279) @ 52wka,l,m,b,c,n NCT01255761 · Phase 4 · registry result, not featured evidence show 3 more doses24.9% (n=365) @ 52wk NCT01255761 · Phase 4 · registry result, not featured evidence 31.5% (n=238) @ 52wk NCT01255761 · Phase 4 · registry result, not featured evidence 21.5% (n=368) @ 52wk NCT01255761 · Phase 4 · registry result, not featured evidence |
| DAS28 Remission responder rate · % of participants | 73.3% (n=105) vs 58.9% (n=112) placebo @ 78wk*a,b,j NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 77 Participants as posted show 1 more dose27.4% (n=259) vs 58.9% (n=112) placebo @ 78wk* NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 71 Participants as posted | 29% (n=69) vs 5.8% (n=69) placebo @ 34wk400 mga,b,j NCT00580840 · Phase 4 · registry result, not featured evidence · combination show 1 more dose18.6% (n=70) vs 5.8% (n=69) placebo @ 34wk200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination |
| DAS28-CRP absolute change · score | -2.51 vs -2.65 ABBV-3373 score @ 12wke,b,c NCT03823391 · Phase 2 · registry result, not featured evidence | -1.7 vs -0.84 placebo score @ 12wke,b,c NCT00717236 · Phase 3 · registry result, not featured evidence |
| DAS28-ESR absolute change · score | -2.8 vs -1.8 placebo score @ 26wkb,c,o NCT00870467 · Phase 3 · registry result, not featured evidence | -3.901 vs -3.436 placebo score @ 104wkQ2Wa,b,c,o NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 3 more doses0.511 vs 1.145 placebo score @ 104wkQ2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination -4.252 vs -3.436 placebo score @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 0.414 vs 1.145 placebo score @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination |
| DAS28-ESR absolute change · score No placebo or comparator arm | -3.7 score @ 52wka,b,c,d NCT00870467 · Phase 3 · registry result, not featured evidence show 1 more dose-1.9 score @ 52wk NCT00870467 · Phase 3 · registry result, not featured evidence | -3.222 scoreb,c,d NCT00175877 · Phase 3 3 other source trials-2.14 score @ 52wk NCT01255761 · Phase 4 · registry result, not featured evidence -2.26 score @ 52wk NCT01255761 · Phase 4 · registry result, not featured evidence -2.99 score NCT00160641 · Phase 3 · registry result, not featured evidence |
| DAS28-ESR LDAS responder rate · % of participants | 35.5% (n=454) vs 33.5% (n=454) ADA+MTX @ 104wka,b NCT01500278 · Phase 4 · registry result, not featured evidence · combination show 2 more doses45.6% (n=353) vs 42.4% (n=361) ADA+MTX @ 104wk NCT01500278 · Phase 4 · registry result, not featured evidence · combination 47.7% (n=310) vs 46.6% (n=298) ADA+MTX @ 104wk NCT01500278 · Phase 4 · registry result, not featured evidence · combination | 35.5% (n=454) vs 33.5% (n=454) ADA+MTX @ 104wka,b NCT01500278 · Phase 4 · registry result, not featured evidence · combination show 2 more doses45.6% (n=353) vs 42.4% (n=361) ADA+MTX @ 104wk NCT01500278 · Phase 4 · registry result, not featured evidence · combination 47.7% (n=310) vs 46.6% (n=298) ADA+MTX @ 104wk NCT01500278 · Phase 4 · registry result, not featured evidence · combination |
| DAS28-ESR Remission responder rate · % of participants | 30.4% (n=171) vs 14.7% (n=163) placebo @ 26wk*b,c,o NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 52 participants as posted | 52.4% (n=84) vs 44.3% (n=79) placebo @ 104wkQ2Wa,b,c,o NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 1 more dose63.5% (n=126) vs 44.3% (n=79) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination |
| DAS28-ESR Remission responder rate · % of participants No placebo or comparator arm | 46.6% (n=133) @ 52wk*a,l,m,b,c NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 62 participants as posted show 1 more dose0% (n=5) @ 52wk* NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 0 participants as posted | 23.3% (n=279) @ 52wka,l,m,b,c NCT01255761 · Phase 4 · registry result, not featured evidence show 3 more doses17.8% (n=365) @ 52wk NCT01255761 · Phase 4 · registry result, not featured evidence 21.8% (n=238) @ 52wk NCT01255761 · Phase 4 · registry result, not featured evidence 14.9% (n=368) @ 52wk NCT01255761 · Phase 4 · registry result, not featured evidence |
| Erosion absolute change · score | 3 vs 6.4 Methotrexate score @ 104wka,b NCT00195663 · Phase 3 · registry result, not featured evidence show 1 more dose1 vs 6.4 Methotrexate score @ 104wk NCT00195663 · Phase 3 · registry result, not featured evidence · combination | 0 vs 0 placebo score @ 104wkQ2Wa,b NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 3 more doses0 vs 0 placebo score @ 104wkQ2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 0 vs 0 placebo score @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 0 vs 0 placebo score @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination |
| EULAR Good, Moderate responder rate · % of participants | 63% (n=64) vs 63% (n=64) AbbVie Adalimumab @ 24wkm,b,c NCT03172325 · Phase 3 · registry result, not featured evidence | 77.3% (n=22) vs 75% (n=8) placebo @ 24wk*m,b,c NCT01147341 · Phase 4 · registry result, not featured evidence · converted to % from 17 participants as posted |
| HAQ-DI absolute change · score No placebo or comparator arm | -0.52 score @ 520wkb,c,d NCT00195650 · Phase 3 · registry result, not featured evidence | -0.674 scoreb,c,d NCT00175877 · Phase 3 2 other source trials-0.567 score NCT00160641 · Phase 3 · registry result, not featured evidence -0.305 score NCT00160693 · Phase 3 · registry result, not featured evidence |
| Modified Sharp absolute change · score No placebo or comparator arm | 1.6 score @ 52wka,b,c,p NCT00870467 · Phase 3 · registry result, not featured evidence show 1 more dose9.6 score @ 52wk NCT00870467 · Phase 3 · registry result, not featured evidence | 0.99 score @ 104wkb,c,p NCT00160641 · Phase 3 · registry result, not featured evidence |
| mTSS no Progression responder rate · % of participants | 46.2% (n=39) vs 51.4% (n=35) Standard of Care @ 104wkf,b,c NCT01162421 · Phase 4 · registry result, not featured evidence | 79.2% (n=72) vs 69.3% (n=75) placebo @ 104wkQ2Wa,f,b,c NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 3 more doses90.3% (n=72) vs 80% (n=75) placebo @ 104wkQ2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 77.9% (n=113) vs 69.3% (n=75) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 84.1% (n=113) vs 80% (n=75) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination |
| Patient Global Assessment absolute change · score | -23.6 vs -30.6 Standard of Care score @ 104wkb,c,q NCT01162421 · Phase 4 · registry result, not featured evidence | -35.58 vs -16.37 placebo score @ 34wk400 mga,b,c,q NCT00580840 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-33.07 vs -16.37 placebo score @ 34wk200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination |
| RAMRIS Synovitis absolute change · score | -3.38 vs -3.88 placebo score @ 78wka,f,b,c,r NCT00420927 · Phase 4 · registry result, not featured evidence · combination show 1 more dose-3.25 vs -3.88 placebo score @ 78wk NCT00420927 · Phase 4 · registry result, not featured evidence · combination | -0.4 vs 0.2 placebo score @ 2wkf,b,c,r NCT01235598 · Phase 3 · registry result, not featured evidence |
| SDAI absolute change · score | -27.42 vs -28.5 ABBV-3373 score @ 12wke,b,c NCT03823391 · Phase 2 · registry result, not featured evidence | -19.66 vs -10.78 placebo score @ 12wke,b,c NCT00717236 · Phase 3 · registry result, not featured evidence |
| SDAI Remission responder rate · % of participants | 52.4% (n=105) vs 45.5% (n=112) placebo @ 78wk*a,f,b,g NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 55 Participants as posted show 1 more dose15.1% (n=259) vs 45.5% (n=112) placebo @ 78wk* NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted | 53.6% (n=84) vs 41.8% (n=79) placebo @ 104wkQ2Wa,f,b,g NCT01521923 · Phase 3 · registry result, not featured evidence · combination show 1 more dose57.1% (n=126) vs 41.8% (n=79) placebo @ 104wkQ4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination |
| SDAI Remission responder rate · % of participants No placebo or comparator arm | 37.9% (n=66) @ 48wk*maximum tolerated dosea,f,b,c,s NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 25 Participants as posted show 3 more doses39.7% (n=58) @ 48wk*maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 23 Participants as posted 44.3% (n=61) @ 48wk*reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted 44.3% (n=61) @ 48wk*reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted | 25.8% (n=120) @ 136wkf,b,c,s NCT00843778 · Phase 3 · registry result, not featured evidence |
| SF-36 MCS absolute change · score | 7.1 vs 6.5 Methotrexate score @ 52wka,m,b,t NCT00195663 · Phase 3 · registry result, not featured evidence show 1 more dose7.2 vs 6.5 Methotrexate score @ 52wk NCT00195663 · Phase 3 · registry result, not featured evidence · combination | 5.51 vs 4.9 placebo score @ 34wk400 mga,m,b,t NCT00580840 · Phase 4 · registry result, not featured evidence · combination show 1 more dose8.59 vs 4.9 placebo score @ 34wk200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination |
| SF-36 PCS absolute change · score | 12.6 vs 12.5 Methotrexate score @ 52wka,m,b,t NCT00195663 · Phase 3 · registry result, not featured evidence show 1 more dose16.7 vs 12.5 Methotrexate score @ 52wk NCT00195663 · Phase 3 · registry result, not featured evidence · combination | 10.54 vs 5.09 placebo score @ 34wk400 mga,m,b,t NCT00580840 · Phase 4 · registry result, not featured evidence · combination show 1 more dose9.65 vs 5.09 placebo score @ 34wk200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination |
| Dropout rate | 23.2%40 mg every other weeku NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 20.8%20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 —maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination —reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 24.8%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence 66.7% NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 32.5% NCT01162421 · Phase 4 · registry result, not featured evidence 10.3%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 12.3%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT03172325 · Phase 3 · registry result, not featured evidence 9.2%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 6.1%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 7%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 15.3%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 39.4%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 26.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination 36% NCT00690573 · Phase 3 · registry result, not featured evidence 9.4%DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 62.1% NCT00195650 · Phase 3 · registry result, not featured evidence 5%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence 8.2%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 11.2%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 22.7%40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 47.6%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence 1.7%40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 4.1%80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 0%Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 2%40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 9.1%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 2.3%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 2%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence —Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 64%40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | —Q2Wv NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 show 40 more results—Q4W NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 41.3% NCT00175877 · Phase 3 66.7% NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 31.1% NCT01443364 · Phase 4 · registry result, not featured evidence 47.7%CDAI to Assess Response to Cimzia NCT01255761 · Phase 4 · registry result, not featured evidence 49.3%RAPID3 to Assess Response to Cimzi NCT01255761 · Phase 4 · registry result, not featured evidence 3.7% NCT01147341 · Phase 4 · registry result, not featured evidence —400 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination —200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination 2.7%Cimzia NCT00993668 · Phase 4 · registry result, not featured evidence —Cimzia (Single Blind) NCT00993668 · Phase 4 · registry result, not featured evidence 2.4%Open-label Cimzia (Cimzia in Feede NCT02319642 · Phase 3 · registry result, not featured evidence 4.2%Open-label Cimzia (Placebo in Feed NCT02319642 · Phase 3 · registry result, not featured evidence — NCT02151851 · Phase 3 · registry result, not featured evidence · combination 55.8% NCT01519791 · Phase 3 · registry result, not featured evidence · combination 15.7%Q2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 11.8%Q4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 31.1% NCT01451203 · Phase 3 · registry result, not featured evidence · combination 30.2%400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 25%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 32.6%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 41.8%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 14.3% NCT01235598 · Phase 3 · registry result, not featured evidence 26.7% NCT00843778 · Phase 3 · registry result, not featured evidence 8.3% NCT01374971 · Phase 3 · registry result, not featured evidence 39% NCT00160641 · Phase 3 · registry result, not featured evidence 29.4%200mg NCT00993317 · Phase 3 · registry result, not featured evidence · combination 8.3% NCT00753454 · Phase 3 · registry result, not featured evidence 9.4% NCT00717236 · Phase 3 · registry result, not featured evidence 58.5% NCT00160693 · Phase 3 · registry result, not featured evidence 12.5%200 mg NCT00674362 · Phase 3 · registry result, not featured evidence 29.3%200mg NCT00791921 · Phase 3 · registry result, not featured evidence 23.5%400 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 19.5%200 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 29.2%100 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 30.3% NCT04740814 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —40 mg every other weeku NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 —20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 —maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination —reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 1.3%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence — NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 12.5% NCT01162421 · Phase 4 · registry result, not featured evidence 3.9%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 4.5%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT03172325 · Phase 3 · registry result, not featured evidence 3.1%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 0%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 3.1%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 9.9%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 11.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination — NCT00690573 · Phase 3 · registry result, not featured evidence —DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 22.9% NCT00195650 · Phase 3 · registry result, not featured evidence 3%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence 4.4%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 3.4%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 11%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence 1.7%40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 2.5%80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 0%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 2.3%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 2%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence —Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | —Q2Wv NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 show 40 more results—Q4W NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 16.1% NCT00175877 · Phase 3 — NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination — NCT01443364 · Phase 4 · registry result, not featured evidence 11.7%CDAI to Assess Response to Cimzia NCT01255761 · Phase 4 · registry result, not featured evidence 7.9%RAPID3 to Assess Response to Cimzi NCT01255761 · Phase 4 · registry result, not featured evidence — NCT01147341 · Phase 4 · registry result, not featured evidence —400 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination —200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination 0.9%Cimzia NCT00993668 · Phase 4 · registry result, not featured evidence —Cimzia (Single Blind) NCT00993668 · Phase 4 · registry result, not featured evidence 1.6%Open-label Cimzia (Cimzia in Feede NCT02319642 · Phase 3 · registry result, not featured evidence 2.1%Open-label Cimzia (Placebo in Feed NCT02319642 · Phase 3 · registry result, not featured evidence — NCT02151851 · Phase 3 · registry result, not featured evidence · combination — NCT01519791 · Phase 3 · registry result, not featured evidence · combination —Q2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination —Q4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 5.6% NCT01451203 · Phase 3 · registry result, not featured evidence · combination 14%400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 16.7%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 14%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 13.6%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 10.7% NCT01235598 · Phase 3 · registry result, not featured evidence 11.5% NCT00843778 · Phase 3 · registry result, not featured evidence — NCT01374971 · Phase 3 · registry result, not featured evidence 18% NCT00160641 · Phase 3 · registry result, not featured evidence 4.7%200mg NCT00993317 · Phase 3 · registry result, not featured evidence · combination 2.4% NCT00753454 · Phase 3 · registry result, not featured evidence 3.9% NCT00717236 · Phase 3 · registry result, not featured evidence 24.1% NCT00160693 · Phase 3 · registry result, not featured evidence 6.3%200 mg NCT00674362 · Phase 3 · registry result, not featured evidence 6.9%200mg NCT00791921 · Phase 3 · registry result, not featured evidence 8.2%400 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 3.7%200 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 4.2%100 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 0%400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 0%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 0%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 9.1% NCT04740814 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 13%40 mg every other weeku NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 16%20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 7.4%maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 4.5%reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 2.7%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence 7.7%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence 1%Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence 0% NCT02451748 · Phase 4 · registry result, not featured evidence · combination 13% NCT01500278 · Phase 4 · registry result, not featured evidence · combination 10.3% NCT01162421 · Phase 4 · registry result, not featured evidence 7.1%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 3.9%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 11.4%ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 6.9%ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT03172325 · Phase 3 · registry result, not featured evidence 7.1%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 3%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 5.1%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 23.7%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 20.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination 24% NCT00690573 · Phase 3 · registry result, not featured evidence 4.1%DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 51.1% NCT00195650 · Phase 3 · registry result, not featured evidence 1%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 4.9%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 3.3%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 6.4%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 1.9%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 22.7%40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 35.9%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence —40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence 0%40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence 2.5%80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 0%Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 12.5%Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 0%40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 2.3%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 4.5%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 0%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence 0%Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 0%New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 40%40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | 0%Q2Wv NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 show 40 more results0%Q4W NCT03357471 · Phase 3 · Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis · phase 3 41.6% NCT00175877 · Phase 3 0% NCT02451748 · Phase 4 · registry result, not featured evidence · combination 13% NCT01500278 · Phase 4 · registry result, not featured evidence · combination 12.1% NCT01443364 · Phase 4 · registry result, not featured evidence 10.6%CDAI to Assess Response to Cimzia NCT01255761 · Phase 4 · registry result, not featured evidence 8.7%RAPID3 to Assess Response to Cimzi NCT01255761 · Phase 4 · registry result, not featured evidence 2.9% NCT01147341 · Phase 4 · registry result, not featured evidence 2.9%400 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination 7.1%200 mg NCT00580840 · Phase 4 · registry result, not featured evidence · combination —Cimzia NCT00993668 · Phase 4 · registry result, not featured evidence 1.8%Cimzia (Single Blind) NCT00993668 · Phase 4 · registry result, not featured evidence 2%Open-label Cimzia (Cimzia in Feede NCT02319642 · Phase 3 · registry result, not featured evidence 6.3%Open-label Cimzia (Placebo in Feed NCT02319642 · Phase 3 · registry result, not featured evidence 6.3% NCT02151851 · Phase 3 · registry result, not featured evidence · combination 10.6% NCT01519791 · Phase 3 · registry result, not featured evidence · combination 4.8%Q2W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 7.1%Q4W NCT01521923 · Phase 3 · registry result, not featured evidence · combination 10.7% NCT01451203 · Phase 3 · registry result, not featured evidence · combination 37.2%400 mg NCT00850343 · Phase 3 · registry result, not featured evidence 25%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 39.5%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence 36.4%200 mg NCT00850343 · Phase 3 · registry result, not featured evidence — NCT01235598 · Phase 3 · registry result, not featured evidence 19.2% NCT00843778 · Phase 3 · registry result, not featured evidence 0% NCT01374971 · Phase 3 · registry result, not featured evidence 35.3% NCT00160641 · Phase 3 · registry result, not featured evidence 9.4%200mg NCT00993317 · Phase 3 · registry result, not featured evidence · combination 3% NCT00753454 · Phase 3 · registry result, not featured evidence 6.1% NCT00717236 · Phase 3 · registry result, not featured evidence 45.8% NCT00160693 · Phase 3 · registry result, not featured evidence 5.2%200 mg NCT00674362 · Phase 3 · registry result, not featured evidence 11.2%200mg NCT00791921 · Phase 3 · registry result, not featured evidence 5.9%400 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 4.9%200 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence 4.2%100 mg NCT00791999 · Phase 2/3 · registry result, not featured evidence —400 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 20%400 mg Q4W NCT04163016 · Phase 1 · registry result, not featured evidence 26.7%200 mg Q2W NCT04163016 · Phase 1 · registry result, not featured evidence 6.1% NCT04740814 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 40 mg every other weeku injection site pain 17.9% (placebo 21.5%) upper respiratory tract infection 16.9% (placebo 11%) headache 11.6% (placebo 5%) NCT00195702 · Phase 3 show 40 more results20 mg weekly injection site pain 17.5% (placebo 21.5%) upper respiratory tract infection 16.5% (placebo 11%) headache 13.2% (placebo 5%) NCT00195702 · Phase 3 maximum tolerated dose liver function test abnormal 8.8% abdominal pain upper 2.9% dry mouth 1.5% NCT03505008 · Phase 4 · registry result, not featured evidence · combination reduced dose dry mouth 3% alanine aminotransferase increased 1.5% cough 1.5% NCT03505008 · Phase 4 · registry result, not featured evidence · combination 40 mg Eow cough 2.7% (placebo 5%) nasopharyngitis 2.7% (placebo 20%) urinary tract infection 1.4% (placebo 0%) NCT02198651 · Phase 4 · registry result, not featured evidence 40 mg Eow nasopharyngitis 10.3% (placebo 20%) upper respiratory tract infection 7.7% (placebo 0%) hepatic enzyme increased 5.1% (placebo 0%) NCT02198651 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.7% (placebo 20%) arthralgia 5.9% (placebo 0%) influenza 4.9% (placebo 10%) NCT02198651 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.3% headache 10.7% upper respiratory tract infection 10.3% NCT01500278 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis 25.6% nasopharyngitis 20.5% alanine aminotransferase increased 15.4% NCT01162421 · Phase 4 · registry result, not featured evidence high dose nausea 10.3% upper respiratory tract infection 7.7% urinary tract infection 7.1% NCT01185288 · Phase 4 · registry result, not featured evidence · combination low dose nausea 9.7% fatigue 9.1% upper respiratory tract infection 9.1% NCT01185288 · Phase 4 · registry result, not featured evidence · combination cough 6.7% (placebo 3.6%) influenza 5.7% (placebo 2.7%) nasopharyngitis 5.7% (placebo 3.6%) NCT00420927 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 11.2% (placebo 6.3%) nasopharyngitis 8.9% (placebo 3.6%) alanine aminotransferase increased 6.2% (placebo 2.7%) NCT00420927 · Phase 4 · registry result, not featured evidence · combination injection site reaction 8.8% headache 5.9% nausea 5.9% NCT03172325 · Phase 3 · registry result, not featured evidence 20 mg MTX nasopharyngitis 11.2% headache 9.2% alopecia 8.2% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 10 mg MTX nausea 13.1% alopecia 6.1% diarrhoea 6.1% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 5 mg MTX diarrhoea 6% headache 6% nasopharyngitis 6% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2.5 mg MTX nausea 7.1% arthralgia 6.1% abdominal pain upper 4.1% NCT01185301 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 22.6% headache 21.5% nausea 17.5% NCT00195663 · Phase 3 · registry result, not featured evidence nasopharyngitis 30.2% headache 20.5% upper respiratory tract infection 18.7% NCT00195663 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 56% upper respiratory tract infection 56% influenza 32% NCT00690573 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.2% (placebo 16.6%) hepatic function abnormal 8.2% (placebo 5.5%) alanine aminotransferase increased 7.6% (placebo 3.7%) NCT00870467 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 46.3% rheumatoid arthritis 25.4% sinusitis 24.9% NCT00195650 · Phase 3 · registry result, not featured evidence 40 mg/0.8 mL nasopharyngitis 4% respiratory disorder 4% headache 3% NCT01231321 · Phase 3 · registry result, not featured evidence 40 mg every other week nausea 5.5% (placebo 5.3%) headache 4.9% (placebo 5.3%) nasopharyngitis 4.9% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 6.6% (placebo 5.3%) upper respiratory tract infection 2.6% (placebo 7%) cough 0% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 80 mg monthly upper respiratory tract infection 3.2% (placebo 7%) nasopharyngitis 2.7% (placebo 5.3%) cough 0% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 80 mg monthly nausea 6.2% (placebo 5.3%) upper respiratory tract infection 5.2% (placebo 7%) headache 4.7% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 40 mg or 80 mg every other week nasopharyngitis 60.2% adverse drug reaction 29.5% antinuclear antibody positive 15.9% NCT00603993 · Phase 3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 45% adverse drug reaction 23.6% dna antibody positive 16.2% NCT00235872 · Phase 3 · registry result, not featured evidence 40 mg EOW upper respiratory tract infection 14% (placebo 11.7%) injection site pruritus 5.8% (placebo 0%) nasopharyngitis 5.8% (placebo 6.7%) NCT00538902 · Phase 2/3 · registry result, not featured evidence 80 mg EOW upper respiratory tract infection 12.4% (placebo 11.7%) nasopharyngitis 7.4% (placebo 6.7%) injection site pruritus 4.1% (placebo 0%) NCT00538902 · Phase 2/3 · registry result, not featured evidence urinary tract infection 11.8% abdominal discomfort 5.9% arthralgia 5.9% NCT03823391 · Phase 2 · registry result, not featured evidence nasopharyngitis 12.5% bronchitis 6.3% drug hypersensitivity 6.3% NCT03823391 · Phase 2 · registry result, not featured evidence nasopharyngitis 15.9% rheumatoid arthritis 9.1% upper respiratory tract infection 9.1% NCT01752855 · Phase 2 · registry result, not featured evidence nasopharyngitis 13.6% cystitis 9.1% upper respiratory tract infection 9.1% NCT01752855 · Phase 2 · registry result, not featured evidence 40 mg every other week nasopharyngitis 10% cystitis 8% nausea 8% NCT01712178 · Phase 2 · registry result, not featured evidence pharyngitis 1.6% rash erythematous 1.6% protein urine present 0% NCT01561313 · Phase 2 · registry result, not featured evidence protein urine present 1.6% pharyngitis 0% rash erythematous 0% NCT01561313 · Phase 2 · registry result, not featured evidence 40 mg Eow nasopharyngitis 60% diarrhoea 24% pruritus 20% NCT00235833 · Phase 2 · registry result, not featured evidence | show 34 more resultsnasopharyngitis 15.3% headache 10.7% upper respiratory tract infection 10.3% NCT01500278 · Phase 4 · registry result, not featured evidence · combination influenza 11.4% arthralgia 6.8% bronchitis 5.3% NCT01443364 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 10.4% urinary tract infection 10.4% bronchitis 6% NCT01255761 · Phase 4 · registry result, not featured evidence urinary tract infection 10.6% upper respiratory tract infection 10% sinusitis 7.6% NCT01255761 · Phase 4 · registry result, not featured evidence upper respiratory infections 18.5% (placebo 0%) rash 11.8% (placebo 0%) bronchitis 8.8% (placebo 0%) NCT01147341 · Phase 4 · registry result, not featured evidence 400 mg upper respiratory tract infection 11.6% (placebo 14.5%) urinary tract infection 8.7% (placebo 10.1%) arthralgia 7.2% (placebo 2.9%) NCT00580840 · Phase 4 · registry result, not featured evidence · combination 200 mg upper respiratory tract infection 7.1% (placebo 14.5%) urinary tract infection 7.1% (placebo 10.1%) arthralgia 1.4% (placebo 2.9%) NCT00580840 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 9.1% (placebo 5.3%) headache 7.3% (placebo 13.2%) nausea 5.5% (placebo 5.3%) NCT00993668 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 15.5% anaemia 5.6% liver function test abnormal 4.4% NCT02319642 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 13.7% anaemia 5.3% liver function test abnormal 5.3% NCT02319642 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 15.8% (placebo 13.3%) latent tuberculosis 7.6% (placebo 6.2%) liver function test abnormal 7% (placebo 3.5%) NCT02151851 · Phase 3 · registry result, not featured evidence · combination nausea 12.6% (placebo 10.1%) upper respiratory tract infection 10.9% (placebo 5.1%) urinary tract infection 7.3% (placebo 7.4%) NCT01519791 · Phase 3 · registry result, not featured evidence · combination Q2W urinary tract infection 6% (placebo 2.5%) nasopharyngitis 4.8% (placebo 6.2%) hypercholesterolaemia 2.4% (placebo 3.7%) NCT01521923 · Phase 3 · registry result, not featured evidence · combination Q4W nasopharyngitis 10.2% (placebo 6.2%) hypercholesterolaemia 6.3% (placebo 3.7%) latent tuberculosis 5.5% (placebo 0%) NCT01521923 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 44% (placebo 34.4%) hepatic function abnormal 32.1% (placebo 30.6%) nausea 24.5% (placebo 19.1%) NCT01451203 · Phase 3 · registry result, not featured evidence · combination 400 mg nasopharyngitis 44.2% pharyngitis 16.3% bronchitis 14% NCT00850343 · Phase 3 · registry result, not featured evidence 200 mg rheumatoid arthritis 25% bronchitis 16.7% constipation 16.7% NCT00850343 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 41.9% eczema 27.9% upper respiratory tract infection 20.9% NCT00850343 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 38.2% eczema 18.2% pharyngitis 15.5% NCT00850343 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 9.2% diarrhoea 6.2% nasopharyngitis 6.2% NCT00843778 · Phase 3 · registry result, not featured evidence flare of rheumatoid arthritis 8.3% headache 8.3% injection site reaction 8.3% NCT01374971 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 16% hypertension 13.6% rheumatoid arthritis 13.4% NCT00160641 · Phase 3 · registry result, not featured evidence 200mg upper respiratory tract infection 14.1% (placebo 11.9%) nasopharyngitis 11.8% (placebo 9.5%) abdominal pain upper 5.9% (placebo 4.8%) NCT00993317 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 13.7% NCT00753454 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 7.3% (placebo 5.3%) headache 5.4% (placebo 5.3%) rheumatoid arthritis 4.4% (placebo 7.7%) NCT00717236 · Phase 3 · registry result, not featured evidence nasopharyngitis 35.1% upper respiratory tract infection 23.1% back pain 22.4% NCT00160693 · Phase 3 · registry result, not featured evidence 200 mg nasopharyngitis 10.4% (placebo 11.2%) upper respiratory tract infection 6.3% (placebo 4.1%) urinary tract infection 6.3% (placebo 5.1%) NCT00674362 · Phase 3 · registry result, not featured evidence 200mg nasopharyngitis 17.2% (placebo 14%) rash 8.6% (placebo 0%) eczema 5.2% (placebo 2.6%) NCT00791921 · Phase 3 · registry result, not featured evidence 400 mg nasopharyngitis 15.3% (placebo 11.7%) hepatic function abnormal 5.9% (placebo 5.2%) bronchitis 4.7% (placebo 1.3%) NCT00791999 · Phase 2/3 · registry result, not featured evidence 200 mg nasopharyngitis 13.4% (placebo 11.7%) pharyngitis 6.1% (placebo 3.9%) rash 4.9% (placebo 1.3%) NCT00791999 · Phase 2/3 · registry result, not featured evidence 100 mg hepatic function abnormal 11.1% (placebo 5.2%) nasopharyngitis 11.1% (placebo 11.7%) pharyngitis 6.9% (placebo 3.9%) NCT00791999 · Phase 2/3 · registry result, not featured evidence 400 mg Q4W influenza 40% cystitis 20% foetal vascular malperfusion 20% NCT04163016 · Phase 1 · registry result, not featured evidence 200 mg Q2W covid-19 40% headache 20% hypertension 13.3% NCT04163016 · Phase 1 · registry result, not featured evidence upper respiratory tract infection 9.1% nausea 6.1% rheumatoid arthritis 6.1% NCT04740814 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eTrial phases differ: Phase 2 versus Phase 3.
- fTrial phases differ: Phase 4 versus Phase 3.
- gAssessment timepoints differ: 78 weeks versus 104 weeks.
- hAssessment timepoints differ: 26 weeks versus 136 weeks.
- iAssessment timepoints differ: 104 weeks versus 12 weeks.
- jAssessment timepoints differ: 78 weeks versus 34 weeks.
- kAssessment timepoints differ: 12 weeks versus 104 weeks.
- lThe reported result categories differ.
- mTrial phases differ: Phase 3 versus Phase 4.
- nAssessment timepoints differ: 26 weeks versus 52 weeks.
- oAssessment timepoints differ: 26 weeks versus 104 weeks.
- pAssessment timepoints differ: 52 weeks versus 104 weeks.
- qAssessment timepoints differ: 104 weeks versus 34 weeks.
- rAssessment timepoints differ: 78 weeks versus 2 weeks.
- sAssessment timepoints differ: 48 weeks versus 136 weeks.
- tAssessment timepoints differ: 52 weeks versus 34 weeks.
- uPopulation comparability has not been reviewed for these studies.
- vPopulation comparability has not been reviewed for 39 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 5 more results
show 5 more results
show 5 more results
+ 200 further endpoints in the CSV export.
certolizumab pegol
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 5 more results
show 1 more result
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 1 more result
+ 66 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · certolizumab pegol's landscape